364 results
Search Results
2. Anti-Immune Complex Antibodies Enhance Affinity and Specificity of Primary Antibodies
- Author
-
Ullman, Edwin F., Milburn, Gary, Jelesko, John, Radika, Kesavan, Pirio, Marcel, Kempe, Thomas, and Skold, Carl
- Published
- 1993
3. Amino Acid Sequences of Two Mouse Immunoglobulin Lambda Chains
- Author
-
Appella, Ettore
- Published
- 1971
4. Immunoglobulin Synthesis and Secretion, III. Incorporation of Glucosamine into Immunoglobulin on Polyribosomes
- Author
-
Sherr, Charles J. and Uhr, Jonathan W.
- Published
- 1969
5. Two Types of Lambda Polypeptide Chains in Human Immunoglobulins Based on an Amino Acid Substitution at Position 190
- Author
-
Appella, Ettore and Ein, Daniel
- Published
- 1967
6. Chemical Identification of Specific Immunoglobulins as the Product of a Cell-Free System from Plasmocytoma Tumors
- Author
-
Mach, Bernard, Koblet, Hans, and Gros, Denise
- Published
- 1968
7. The Amino-Terminal Amino Acid Sequences of Rabbit Immunoglobulin Light Chains
- Author
-
Doolittle, Russell F.
- Published
- 1966
8. B cell receptors and free antibodies have different antigen-binding kinetics.
- Author
-
García-Sánchez, Miguel, Castro, Mario, and Faro, José
- Subjects
B cell receptors ,RECEPTOR antibodies ,GERMINAL centers ,B cells ,MOLECULAR rotation - Abstract
Since the pioneering works of Berg and Purcell, discriminating between diffusion followed by binding has played a central role in understanding cell signaling. B cell receptors (BCR) and antibodies (Ab) challenge that simplified view as binding to the antigen follows after a chain of diffusion and rotations, including whole molecule rotation and independent tilts and twists of their Fab arms due to their Yshaped structure and flexibility. In this paper, we combine analytical calculations with Brownian simulations to derive the first-passage times due to these three rotations positioning the Fab paratopes at a proper distance and orientation required for antigen binding. Our results indicate that when measuring Ab--Ag effective kinetic binding rates, using experimental methods in which the analyte is in solution only gives values proportional to the intrinsic binding rates, k
+ , and k- , for values of k+ up to 109 s-1 . Beyond that, a plateau of the effective 3D on rate between 108 M-1 s-1 and 109 M-1 s-1 is attained. Additionally, for BCR--Ag interactions, the effective 2D on and off binding rates can only be inferred from the corresponding effective 3D on and off rates for values of effective 3D on rates lower than 106 M-1 s-1 . This is highly relevant when trying to relate BCR--antigen-binding strength and B cell response, especially during germinal center reactions. Therefore, there is a pressing need to reexamine our current understanding of the BCR--antigen kinetic rates in germinal centers using the latest experimental assays for BCR--Ag interactions. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
9. Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody.
- Author
-
Meijers, Matthijs, Vanshylla, Kanika, Gruell, Henning, Klein, Florian, and Lässig, Michael
- Subjects
HIV ,VIRAL antibodies ,IMMUNOGLOBULINS ,VIRAL load ,INFECTION prevention - Abstract
Broadly neutralizing antibodies are promising candidates for treatment and prevention of HIV-1 infections. Such antibodies can temporarily suppress viral load in infected individuals; however, the virus often rebounds by escape mutants that have evolved resistance. In this paper, we map a fitness model of HIV-1 interacting with broadly neutralizing antibodies using in vivo data from a recent clinical trial. We identify two fitness factors, antibody dosage and viral load, that determine viral reproduction rates reproducibly across different hosts. The model successfully predicts the escape dynamics of HIV-1 in the course of an antibody treatment, including a characteristic frequency turnover between sensitive and resistant strains. This turnover is governed by a dosage-dependent fitness ranking, resulting from an evolutionary trade-off between antibody resistance and its collateral cost in drug-free growth. Our analysis suggests resistance-cost tradeoff curves as a measure of antibody performance in the presence of resistance evolution. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Nanobodies and chemical cross-links advance the structural and functional analysis of PI3Kα.
- Author
-
Hart, Jonathan R., Xiao Liu, Chen Pan, Anyi Liang, Ueno, Lynn, Yingna Xu, Quezada, Alexandra, Xinyu Zou, Su Yang, Qingtong Zhou, Schoonooghe, Steve, Hassanzadeh-Ghassabeh, Gholamreza, Tian Xia, Wenqing Shui, Dehua Yang, Vogt, Peter K., and Ming-Wei Wang
- Subjects
IMMUNOGLOBULINS ,FUNCTIONAL analysis ,ENZYME activation ,MASS spectrometry ,FLEXIBLE packaging ,PHOSPHATIDYLINOSITOL 3-kinases - Abstract
Nanobodies and chemical cross-linking were used to gain information on the identity and positions of flexible domains of PI3Kα. The application of chemical cross-linking mass spectrometry (CXMS) facilitated the identification of the p85 domains BH, cSH2, and SH3 as well as their docking positions on the PI3Kα catalytic core. Binding of individual nanobodies to PI3Kα induced activation or inhibition of enzyme activity and caused conformational changes that could be correlated with enzyme function. Binding of nanobody Nb3-126 to the BH domain of p85α substantially improved resolution for parts of the PI3Kα complex, and binding of nanobody Nb3-159 induced a conformation of PI3Kα that is distinct from known PI3Kα structures. The analysis of CXMS data also provided mechanistic insights into the molecular underpinning of the flexibility of PI3Kα. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice.
- Author
-
Murphy, Andrew J., Macdonald, Lynn E., Stevens, Sean, Karow, Margaret, Dore, Anthony T., Pobursky, Kevin, Huang, Tammy T., Poueymirou, William T., Esau, Lakeisha, Meola, Melissa, Mikulka, Warren, Krueger, Pamela, Fairhurst, Jeanette, Valenzuela, David M., Papadopoulos, Nicholas, and Yancopoulos, George D.
- Subjects
IMMUNOGLOBULINS ,GENES ,LABORATORY mice ,THERAPEUTICS ,IMMUNE system - Abstract
Mice genetically engineered to be humanized for their Ig genes allow for human antibody responses within a mouse background (HumAb mice), providing a valuable platform for the generation of fully human therapeutic antibodies. Unfortunately, existing HumAb mice do not have fully functional immune systems, perhaps because of the manner in which their genetic humanization was carried out. Heretofore, HumAb mice have been generated by disrupting the endogenous mouse ig genes and simultaneously introducing human Ig transgenes at a different and random location; KO-plus-transgenic humanization. As we describe in the companion paper, we attempted to make mice that more efficiently use human variable region segments in their humoral responses by precisely replacing 6 Mb of mouse Ig heavy and kappa light variable region germ-line gene segments with their human counterparts while leaving the mouse constant regions intact, using a unique in situ humanization approach. We reasoned the introduced human variable region gene segments would function indistinguishably in their new genetic location, whereas the retained mouse constant regions would allow for optimal interactions and selection of the resulting antibodies within the mouse environment. We show that these mice, termed Veloclmmune mice because they were generated using VelociGene technology, efficiently produce human:mouse hybrid antibodies (that are rapidly convertible to fully human antibodies) and have fully functional humoral immune systems indistinguishable from those of WT mice. The efficiency of the Veloclmmune approach is confirmed by the rapid progression of 10 different fully human antibodies into human clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
12. Synthesis and secretion of gammaglobulin by lymph node cells: the acquisition of carbohydrate residues of immunoglobulin in relation to interchain disulfide bond formation (heavy and light chains-murine myeloma-mannose-glucosamine-galactose)
- Author
-
E W, Sutherland, D H, Zimmerman, and M, Kern
- Subjects
Chromatography, Paper ,Galactose ,Immunoglobulins ,Neoplasms, Experimental ,In Vitro Techniques ,Sulfides ,Tritium ,Mice ,Myeloma Proteins ,Leucine ,Centrifugation, Density Gradient ,Animals ,Carbohydrate Metabolism ,Disulfides ,Lymph Nodes ,Rabbits ,gamma-Globulins ,Biological Sciences: Biochemistry ,Immunoelectrophoresis ,Mannose ,Cells, Cultured - Abstract
Acquisition of carbohydrates in the disulfide-linked heavy (H) and light (L) chain molecules of murine myeloma (ADJPC5), i.e., HH, HHL, and LHHL, was investigated. That some mannose and glucosamine residues are acquired by immunoglobulin precursor molecules was demonstrated by the detection of glucosamine and mannose in HH, HHL, and LHHL. In contrast, galactose was observed solely in LHHL molecules, which have an identical electrophoretic mobility to the secreted product. Furthermore, as judged from cells incubated with [(3)H]leucine, the more juvenile molecules HH and HHL were predominant in the rough microsome fraction, whereas LHHL was the principal molecular species in the smooth microsome fraction. Findings of this type were not observed in rabbit lymph node cells. Thus, galactose, as well as mannose and glucosamine, were found in the more juvenile molecule known for this species (HL). Moreover, the ratio of HL:LHHL, as judged from cells incubated with [(3)H]leucine, was about the same in rough and smooth microsomes.
- Published
- 1972
13. Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia.
- Author
-
Blachly JS, Ruppert AS, Zhao W, Long S, Flynn J, Flinn I, Jones J, Maddocks K, Andritsos L, Ghia EM, Rassenti LZ, Kipps TJ, de la Chapelle A, and Byrd JC
- Subjects
- Alleles, Base Sequence, Complementarity Determining Regions chemistry, Complementarity Determining Regions genetics, Genome, Humans, Immunoglobulin Variable Region genetics, Molecular Sequence Data, Polymerase Chain Reaction, Prognosis, Sequence Homology, Nucleic Acid, Transcriptome, VDJ Recombinases genetics, Immunoglobulins chemistry, Leukemia, Lymphocytic, Chronic, B-Cell immunology, Sequence Analysis, RNA methods, Somatic Hypermutation, Immunoglobulin
- Abstract
Immunoglobulins (Ig) are produced by B lymphocytes as secreted antibodies or as part of the B-cell receptor. There is tremendous diversity of potential Ig transcripts (>1 × 10(12)) as a result of hundreds of germ-line gene segments, random nucleotide incorporation during joining of gene segments into a complete transcript, and the process of somatic hypermutation at individual nucleotides. This recombination and mutation process takes place in the maturing B cell and is responsible for the diversity of potential epitope recognition. Cancers arising from mature B cells are characterized by clonal production of Ig heavy (IGH@) and light chain transcripts, although whether the sequence has undergone somatic hypermutation is dependent on the maturation stage at which the neoplastic clone arose. Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults and arises from a mature B cell with either mutated or unmutated IGH@ transcripts, the latter having worse prognosis and the assessment of which is routinely performed in the clinic. Currently, IGHV mutation status is assessed by Sanger sequencing and comparing the transcript to known germ-line genes. In this paper, we demonstrate that complete IGH@ V-D-J sequences can be computed from unselected RNA-seq reads with results equal or superior to the clinical procedure: in the only discordant case, the clinical transcript was out-of-frame. Therefore, a single RNA-seq assay can simultaneously yield gene expression profile, SNP and mutation information, as well as IGHV mutation status, and may one day be performed as a general test to capture multidimensional clinically relevant data in CLL.
- Published
- 2015
- Full Text
- View/download PDF
14. Protective human antibodies against a conserved epitope in pre- and postfusion influenza hemagglutinin.
- Author
-
Finney, Joel, Moseman, Annie Park, Kong, Susan, Akiko Watanabe, Shengli Song, Walsh, Richard M., Masayuki Kuraoka, Ryutaro Kotaki, Moseman, E. Ashley, McCarthy, Kevin R., Dongmei Liao, Xiaoe Liang, Xiaoyan Nie, Lavidor, Olivia, Abbott, Richard, Harrison, Stephen C., and Kelsoe, Garnett
- Subjects
INFLUENZA B virus ,HEMAGGLUTININ ,INFLUENZA vaccines ,INFLUENZA ,IMMUNOGLOBULINS - Abstract
Phylogenetically and antigenically distinct influenza A and B viruses (IAV and IBV) circulate in human populations, causing widespread morbidity. Antibodies (Abs) that bind epitopes conserved in both IAV and IBV hemagglutinins (HAs) could protect against disease by diverse virus subtypes. Only one reported HA Ab, isolated from a combinatorial display library, protects against both IAV and IBV. Thus, there has been so far no information on the likelihood of finding naturally occurring human Abs that bind HAs of diverse IAV subtypes and IBV lineages. We have now recovered from several unrelated human donors five clonal Abs that bind a conserved epitope preferentially exposed in the postfusion conformation of IAV and IVB HA2. These Abs lack neutralizing activity in vitro but in mice provide strong, IgG subtype-dependent protection against lethal IAV and IBV infections. Strategies to elicit similar Abs routinely might contribute to more effective influenza vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2.
- Author
-
Xia Rao, Runchu Zhao, Zhou Tong, Shuxin Guo, Weiyu Peng, Kefang Liu, Shihua Li, Lili Wu, Jianyu Tong, Yan Chai, Pu Han, Feiran Wang, Peng Jia, Zhaohui Li, Xin Zhao, Dedong Li, Rong Zhang, Xue Zhang, Weiwei Zou, and Weiwei Li
- Subjects
SARS-CoV-2 Omicron variant ,SARS-CoV-2 ,IMMUNOGLOBULINS ,MONOCLONAL antibodies ,ANGIOTENSIN converting enzyme ,FIREPROOFING agents - Abstract
Currently, monoclonal antibodies (MAbs) targeting the SARS-CoV-2 receptor binding domain (RBD) of spike (S) protein are classified into seven classes based on their binding epitopes. However, most of these antibodies are seriously impaired by SARS-CoV-2 Omicron and its subvariants, especially the recent BQ.1.1, XBB and its derivatives. Identification of broadly neutralizing MAbs against currently circulating variants is imperative. In this study, we identified a "breathing" cryptic epitope in the S protein, named as RBD-8. Two human MAbs, BIOLS56 and IMCAS74, were isolated recognizing this epitope with broad neutralization abilities against tested sarbecoviruses, including SARS-CoV, pangolin-origin coronaviruses, and all the SARS-CoV-2 variants tested (Omicron BA.4/BA.5, BQ.1.1, and XBB subvariants). Searching through the literature, some more RBD-8 MAbs were defined. More importantly, BIOLS56 rescues the immune-evaded antibody, RBD-5 MAb IMCAS-L4.65, by making a bispecific MAb, to neutralize BQ.1 and BQ.1.1, thereby producing an MAb to cover all the currently circulating Omicron subvariants. Structural analysis reveals that the neutralization effect of RBD-8 antibodies depends on the extent of epitope exposure, which is affected by the angle of antibody binding and the number of up-RBDs induced by angiotensin-converting enzyme 2 binding. This cryptic epitope which recognizes non- receptor binding motif (non-RBM) provides guidance for the development of universal therapeutic antibodies and vaccines against COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Nonspecificity fingerprints for clinical-stage antibodies in solution.
- Author
-
Herling, Therese W., Invernizzi, Gaetano, Ausserwöger, Hannes, Bjelke, Jais Rose, Egebjerg, Thomas, Lund, Søren, Lorenzen, Nikolai, and Knowles, Tuomas P. J.
- Subjects
PHYSICAL & theoretical chemistry ,MONOCLONAL antibodies ,IONIC strength ,IMMUNOGLOBULINS ,PROTEIN engineering - Abstract
Monoclonal antibodies (mAbs) have successfully been developed for the treatment of a wide range of diseases. The clinical success of mAbs does not solely rely on optimal potency and safety but also require good biophysical properties to ensure a high developability potential. In particular, nonspecific interactions are a key developability parameter to monitor during discovery and development. Despite an increased focus on the detection of nonspecific interactions, their underlying physicochemical origins remain poorly understood. Here, we employ solution-based microfluidic technologies to characterize a set of clinical-stage mAbs and their interactions with commonly used nonspecificity ligands to generate nonspecificity fingerprints, providing quantitative data on the underlying physical chemistry. Furthermore, the solution-based analysis enables us to measure binding affinities directly, and we evaluate the contribution of avidity in nonspecific binding by mAbs. We find that avidity can increase the apparent affinity by two orders of magnitude. Notably, we find that a subset of these highly developed mAbs show nonspecific electrostatic interactions, even at physiological pH and ionic strength, and that they can form microscale particles with charge-complementary polymers. The group of mAb constructs flagged here for nonspecificity are among the worst performers in independent reports of surface and column-based screens. The solution measurements improve on the state-of-the-art by providing a stand-alone result for individual mAbs without the need to benchmark against cohort data. Based on our findings, we propose a quantitative solution-based nonspecificity score, which can be integrated in the development workflow for biological therapeutics and more widely in protein engineering. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Heteromultimeric sarbecovirus receptor binding domain immunogens primarily generate variant-specific neutralizing antibodies.
- Author
-
Trinity Zang, Kuffour, Edmund Osei, Baharani, Viren A., Canis, Marie, Schmidt, Fabian, Da Silva, Justin, Lercher, Alexander, Chaudhary, Pooja, Hoffmann, Hans-Heinrich, Gazumyan, Anna, Miranda, Ileana C., MacDonald, Margaret R., Rice, Charles M., Nussenzweig, Michel C., Hatziioannou, Theodora, and Bieniasz, Paul D.
- Subjects
B cell receptors ,IMMUNOGLOBULINS ,GERMINAL centers ,B cells ,SARS-CoV-2 ,HAZARD mitigation - Abstract
Vaccination will likely be a key component of strategies to curtail or prevent future sarbecovirus pandemics and to reduce the prevalence of infection and disease by future SARS-CoV-2 variants. A “pan-sarbecovirus” vaccine, that provides maximum possible mitigation of human disease, should elicit neutralizing antibodies with maximum possible breadth. By positioning multiple different receptor binding domain (RBD) antigens in close proximity on a single immunogen, it is postulated that cross-reactive B cell receptors might be selectively engaged. Heteromultimeric vaccines could therefore elicit individual antibodies that neutralize a broad range of viral species. Here, we use model systems to investigate the ability of multimeric sarbecovirus RBD immunogens to expand cross-reactive B cells and elicit broadly reactive antibodies. Homomultimeric RBD immunogens generated higher serum neutralizing antibody titers than the equivalent monomeric immunogens, while heteromultimeric RBD immunogens generated neutralizing antibodies recognizing each RBD component. Moreover, RBD heterodimers elicited a greater fraction of cross-reactive germinal center B cells and cross-reactive RBD binding antibodies than did homodimers. However, when serum antibodies from RBD heterodimer-immunized mice were depleted using one RBD component, neutralization activity against the homologous viral pseudotype was removed, but neutralization activity against pseudotypes corresponding to the other RBD component was unaffected. Overall, simply combining divergent RBDs in a single immunogen generates largely separate sets of individual RBD-specific neutralizing serum antibodies that are mostly incapable of neutralizing viruses that diverge from the immunogen components. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer FcγR-dependent protection in vivo.
- Author
-
Edgar, Julia E., Trezise, Stephanie, Anthony, Robert M., Krammer, Florian, Palese, Peter, Ravetch, Jeffrey V., and Bournazos, Stylianos
- Subjects
INFLUENZA viruses ,INFLUENZA vaccines ,IMMUNOGLOBULINS ,IMMUNE response ,ANTIBODY formation - Abstract
Antibody responses against highly conserved epitopes on the stalk domain of influenza virus hemagglutinin (HA) confer broad protection; however, such responses are limited. To effectively induce stalk-specific immunity against conserved HA epitopes, sequential immunization strategies have been developed based on chimeric HA (cHA) constructs featuring different head domains but the same stalk regions. Immunogenicity studies in small animal models, as well as in humans, revealed that cHA immunogens elicit stalk-specific IgG responses with broad specificity against heterologous influenza virus strains. However, the mechanisms by which these antibodies confer in vivo protection and the contribution of their Fc effector function remain unclear. To characterize the role of Fc-FcγR (Fcγ receptor) interactions to the in vivo protective activity of IgG antibodies elicited in participants in a phase I trial of a cHA vaccine candidate, we performed passive transfer studies of vaccine-elicited IgG antibodies in mice humanized for all classes of FcγRs, as well as in mice deficient for FcγRs. IgG antibodies elicited upon cHA vaccination completely protected FcγR humanized mice against lethal influenza virus challenge, while no protection was evident in FcγR-deficient mice, suggesting a major role for FcγR pathways in the protective function of vaccine-elicited IgG antibodies. These findings have important implications for influenza vaccine development, guiding the design of vaccination approaches with the capacity to elicit IgG responses with optimal Fc effector function. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Structure-based design of nanobodies that inhibit seeding of Alzheimer’s patient–extracted tau fibrils.
- Author
-
Abskharon, Romany, Pan, Hope, Sawaya, Michael R., Seidler, Paul M., Olivares, Eileen J., Yu Chen, Murray, Kevin A., Jeffrey Zhang, Lantz, Carter, Bentzel, Megan, Boyer, David R., Cascio, Duilio, Nguyen, Binh A., Hou, Ke, Xinyi Cheng, Pardon, Els, Williams, Christopher K., Nana, Alissa L., Vinters, Harry V., and Spina, Salvatore
- Subjects
ALZHEIMER'S disease ,TAU proteins ,IMMUNOGLOBULINS ,PROGRESSIVE supranuclear palsy ,SYNTHETIC antibodies - Abstract
Despite much effort, antibody therapies for Alzheimer’s disease (AD) have shown limited efficacy. Challenges to the rational design of effective antibodies include the difficulty of achieving specific affinity to critical targets, poor expression, and antibody aggregation caused by buried charges and unstructured loops. To overcome these challenges, we grafted previously determined sequences of fibril-capping amyloid inhibitors onto a camel heavy chain antibody scaffold. These sequences were designed to cap fibrils of tau, known to form the neurofibrillary tangles of AD, thereby preventing fibril elongation. The nanobodies grafted with capping inhibitors blocked tau aggregation in biosensor cells seeded with postmortem brain extracts from AD and progressive supranuclear palsy (PSP) patients. The tau capping nanobody inhibitors also blocked seeding by recombinant tau oligomers. Another challenge to the design of effective antibodies is their poor blood–brain barrier (BBB) penetration. In this study, we also designed a bispecific nanobody composed of a nanobody that targets a receptor on the BBB and a tau capping nanobody inhibitor, conjoined by a flexible linker. We provide evidence that the bispecific nanobody improved BBB penetration over the tau capping inhibitor alone after intravenous administration in mice. Our results suggest that the design of synthetic antibodies that target sequences that drive protein aggregation may be a promising approach to inhibit the prion-like seeding of tau and other proteins involved in AD and related proteinopathies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. IgG3 subclass antibodies recognize antigenically drifted influenza viruses and SARS-CoV-2 variants through efficient bivalent binding.
- Author
-
Bolton, Marcus J., Santos, Jefferson J. S., Arevalo, Claudia P., Griesman, Trevor, Watson, Megan, Hang Li, Shuk, Bates, Paul, Ramage, Holly, Wilson, Patrick C., and Hensley, Scott E.
- Subjects
INFLUENZA viruses ,SARS-CoV-2 ,VIRAL antibodies ,IMMUNOGLOBULINS ,MONOCLONAL antibodies - Abstract
The constant domains of antibodies are important for effector functions, but less is known about how they can affect binding and neutralization of viruses. Here, we evaluated a panel of human influenza virus monoclonal antibodies (mAbs) expressed as IgG1, IgG2, or IgG3. We found that many influenza virus--specific mAbs have altered binding and neutralization capacity depending on the IgG subclass encoded and that these differences result from unique bivalency capacities of the subclasses. Importantly, subclass differences in antibody binding and neutralization were greatest when the affinity for the target antigen was reduced through antigenic mismatch. We found that antibodies expressed as IgG3 bound and neutralized antigenically drifted influenza viruses more effectively. We obtained similar results using a panel of SARS-CoV-2-specific mAbs and the antigenically advanced B.1.351 and BA.1 strains of SARS-CoV-2. We found that a licensed therapeutic mAb retained neutralization breadth against SARS- CoV-2 variants when expressed as IgG3, but not IgG1. These data highlight that IgG subclasses are not only important for fine- tuning effector functionality but also for binding and neutralization of antigenically drifted viruses. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies.
- Author
-
Lax, Brianna M., Palmeri, Joseph R., Lutz, Emi A., Sheen, Allison, Stinson, Jordan A., Duhamel, Lauren, Santollani, Luciano, Kennedy, Alan, Rothschilds, Adrienne M., Spranger, Stefani, Sansom, David M., and Wittrup, K. Dane
- Subjects
REGULATORY T cells ,CYTOTOXIC T lymphocyte-associated molecule-4 ,DIPHTHERIA toxin ,T cells ,IMMUNOGLOBULINS - Abstract
Anti-CTLA-4 antibodies have successfully elicited durable tumor regression in the clinic; however, long-term benefit is limited to a subset of patients for select cancer indications. The incomplete understanding of their mechanism of action has hindered efforts at improvement, with conflicting hypotheses proposing either antagonism of the CTLA-4: B7 axis or Fc effector-mediated regulatory T cell (Treg) depletion governing efficacy. Here, we report the engineering of a nonantagonistic CTLA-4 binding domain (b1s1e2) that depletes intratumoral Tregs as an Fc fusion. Comparison of b1s1e2-Fc to 9d9, an antagonistic anti-CTLA-4 antibody, allowed for interrogation of the separate contributions of CTLA-4 antagonism and Treg depletion to efficacy. Despite equivalent levels of intratumoral Treg depletion, 9d9 achieved more long-term cures than b1s1e2-Fc in MC38 tumors, demonstrating that CTLA-4 antagonism provided additional survival benefit. Consistent with prior reports that CTLA-4 antagonism enhances priming, treatment with 9d9, but not b1s1e2-Fc, increased the percentage of activated T cells in the tumor-draining lymph node (tdLN). Treg depletion with either construct was restricted to the tumor due to insufficient surface CTLA-4 expression on Tregs in other compartments. Through intratumoral administration of diphtheria toxin in Foxp3-DTR mice, we show that depletion of both intratumoral and nodal Tregs provided even greater survival benefit than 9d9, consistent with Treg-driven restraint of priming in the tdLN. Our data demonstrate that anti-CTLA-4 therapies require both CTLA-4 antagonism and intratumoral Treg depletion for maximum efficacy--but that potential future therapies also capable of depleting nodal Tregs could show efficacy in the absence of CTLA-4 antagonism. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. The molecular mechanism of CD81 antibody inhibition of metastasis.
- Author
-
Abu-Saleh, Niroz, Chiung-Chi Kuo, Wei Jiang, Levy, Ronald, and Levy, Shoshana
- Subjects
TRANSFERRIN receptors ,IMMUNOGLOBULINS ,METASTASIS ,INTEGRINS ,STRUCTURAL components - Abstract
Metastases are reduced in CD81KO mice. In addition, a unique anti-CD81 antibody, 5A6, inhibits metastasis in vivo and invasion and migration in vitro. Here, we probed the structural components of CD81 required for the antimetastatic activity induced by 5A6. We found that the removal of either cholesterol or the intracellular domains of CD81 did not affect inhibition by the antibody. We show that the uniqueness of 5A6 is due not to increased affinity but rather to its recognition of a specific epitope on the large extracellular loop of CD81. Finally, we present a number of CD81 membrane-associated partners that may play a role in mediating the 5A6 antimetastatic attributes, including integrins and transferrin receptors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Fully synthetic platform to rapidly generate tetravalent bispecific nanobody-based immunoglobulins.
- Author
-
Mindrebo, Laetitia Misson, Hejun Liu, Ozorowski, Gabriel, Quoc Tran, Woehl, Jordan, Khalek, Irene, Smith, Jessica M., Barman, Shawn, Fangzhu Zhao, Keating, Celina, Limbo, Oliver, Verma, Megan, Jingjia Liu, Stanfield, Robyn L., Xueyong Zhu, Turner, Hannah L., Sok, Devin, Po-Ssu Huang, Burton, Dennis R., and Ward, Andrew B.
- Subjects
IMMUNOGLOBULINS ,BISPECIFIC antibodies ,SARS-CoV-2 ,MODULAR design ,ANTIGENS - Abstract
Nanobodies bind a target antigen with a kinetic profile similar to a conventional antibody, but exist as a single heavy chain domain that can be readily multimerized to engage antigen via multiple interactions. Presently, most nanobodies are produced by immunizing camelids; however, platforms for animal-free production are growing in popularity. Here, we describe the development of a fully synthetic nanobody library based on an engineered human VH3-23 variable gene and a multispecific antibody-like format designed for biparatopic target engagement. To validate our library, we selected nanobodies against the SARS-CoV-2 receptor-binding domain and employed an on-yeast epitope binning strategy to rapidly map the specificities of the selected nanobodies. We then generated antibody-like molecules by replacing the VH and VL domains of a conventional antibody with two different nanobodies, designed as a molecular clamp to engage the receptor-binding domain biparatopically. The resulting bispecific tetra-nanobody immunoglobulins neutralized diverse SARS-CoV-2 variants with potencies similar to antibodies isolated from convalescent donors. Subsequent biochemical analyses confirmed the accuracy of the on-yeast epitope binning and structures of both individual nanobodies, and a tetra-nanobody immunoglobulin revealed that the intended mode of interaction had been achieved. This overall workflow is applicable to nearly any protein target and provides a blueprint for a modular workflow for the development of multispecific molecules. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Epistasis reduces fitness costs of influenza A virus escape from stem-binding antibodies.
- Author
-
Chung-Young Lee, Raghunathan, Vedhika, Caceres, C. Joaquin, Geiger, Ginger, Seibert, Brittany, Faccin, Flavio Cargnin, Gay, L. Claire, Ferreri, Lucas M., Kaul, Drishti, Wrammert, Jens, Tan, Gene S., Perez, Daniel R., and Lowen, Anice C.
- Subjects
INFLUENZA A virus ,INFLUENZA viruses ,IMMUNOGLOBULINS ,RECOMBINANT viruses ,MEMBRANE fusion ,RECREATION centers - Abstract
The hemagglutinin (HA) stem region is a major target of universal influenza vaccine efforts owing to the presence of highly conserved epitopes across multiple influenza A virus (IAV) strains and subtypes. To explore the potential impact of vaccine-induced immunity targeting the HA stem, we examined the fitness effects of viral escape from stem-binding broadly neutralizing antibodies (stem-bnAbs). Recombinant viruses containing each individual antibody escape substitution showed diminished replication compared to wild-type virus, indicating that stem-bnAb escape incurred fitness costs. A second-site mutation in the HA head domain (N129D; H1 numbering) reduced the fitness effects observed in primary cell cultures and likely enabled the selection of escape mutations. Functionally, this putative permissive mutation increased HA avidity for its receptor. These results suggest a mechanism of epistasis in IAV, wherein modulating the efficiency of attachment eases evolutionary constraints imposed by the requirement for membrane fusion. Taken together, the data indicate that viral escape from stem-bnAbs is costly but highlights the potential for epistatic interactions to enable evolution within the functionally constrained HA stem domain. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. Evolution of nanobodies specific for BCL11A.
- Author
-
Maolu Yin, Izadi, Manizheh, Tenglin, Karin, Viennet, Thibault, Liting Zhai, Ge Zheng, Arthanari, Haribabu, Dassama, Laura M. K., and Orkin, Stuart H.
- Subjects
IMMUNOGLOBULINS ,ZINC-finger proteins ,TRANSCRIPTION factors ,FETAL hemoglobin ,PROTEOLYSIS - Abstract
Transcription factors (TFs) control numerous genes that are directly relevant to many human disorders. However, developing specific reagents targeting TFs within intact cells is challenging due to the presence of highly disordered regions within these proteins. Intracellular antibodies offer opportunities to probe protein function and validate therapeutic targets. Here, we describe the optimization of nanobodies specific for BCL11A, a validated target for the treatment of hemoglobin disorders. We obtained first-generation nanobodies directed to a region of BCL11A comprising zinc fingers 4 to 6 (ZF456) from a synthetic yeast surface display library, and employed error-prone mutagenesis, structural determination, and molecular modeling to enhance binding affinity. Engineered nanobodies recognized ZF6 and mediated targeted protein degradation (TPD) of BCL11A protein in erythroid cells, leading to the anticipated reactivation of fetal hemoglobin (HbF) expression. Evolved nanobodies distinguished BCL11A from its close paralog BCL11B, which shares an identical DNA-binding specificity. Given the ease of manipulation of nanobodies and their exquisite specificity, nanobody-mediated TPD of TFs should be suitable for dissecting regulatory relationships of TFs and gene targets and validating therapeutic potential of proteins of interest. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. prM-reactive antibodies reveal a role for partially mature virions in dengue virus pathogenesis.
- Author
-
Dowd, Kimberly A., Sirohi, Devika, Speer, Scott D., VanBlargan, Laura A., Chen, Rita E., Mukherjee, Swati, Whitener, Bradley M., Govero, Jennifer, Aleshnick, Maya, Larman, Bridget, Sukupolvi-Petty, Soila, Sevvana, Madhumati, Miller, Andrew S., Klose, Thomas, Aihua Zheng, Koenig, Scott, Kielian, Margaret, Kuhn, Richard J., Diamond, Michael S., and Pierson, Theodore C.
- Subjects
DENGUE viruses ,VIRION ,CYTOSKELETAL proteins ,MONOCLONAL antibodies ,IMMUNOGLOBULINS - Abstract
Cleavage of the flavivirus premembrane (prM) structural protein during maturation can be inefficient. The contribution of partially mature flavivirus virions that retain uncleaved prM to pathogenesis during primary infection is unknown. To investigate this question, we characterized the functional properties of newly-generated dengue virus (DENV) prM-reactive monoclonal antibodies (mAbs) in vitro and using a mouse model of DENV disease. Anti-prM mAbs neutralized DENV infection in a virion maturation state--dependent manner. Alanine scanning mutagenesis and cryoelectron microscopy of anti-prM mAbs in complex with immature DENV defined two modes of attachment to a single antigenic site. In vivo, passive transfer of intact anti-prM mAbs resulted in an antibody-dependent enhancement of disease. However, protection against DENV- induced lethality was observed when the transferred mAbs were genetically modified to inhibit their ability to interact with Fcy receptors. These data establish that in addition to mature forms of the virus, partially mature infectious prM
+ virions can also contribute to pathogenesis during primary DENV infections. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
27. Discovery of antibodies and cognate surface targets for ovarian cancer by surface profiling.
- Author
-
Schröfelbauer, Bärbel, Kimes, Patrick K., Hauke, Paige, Reid, Charlotte E., Shao, Kevin, Hill, Sarah J., Irizarry, Rafael, and Hahn, William C.
- Subjects
OVARIAN cancer ,IMMUNOGLOBULINS ,MASS spectrometry ,FLOW cytometry ,MEDICAL screening ,LABOR mobility - Abstract
Although antibodies targeting specific tumor-expressed antigens are the standard of care for some cancers, the identification of cancer-specific targets amenable to antibody binding has remained a bottleneck in development of new therapeutics. To overcome this challenge, we developed a high-throughput platform that allows for the unbiased, simultaneous discovery of antibodies and targets based on phenotypic binding profiles. Applying this platform to ovarian cancer, we identified a wide diversity of cancer targets including receptor tyrosine kinases, adhesion and migration proteins, proteases and proteins regulating angiogenesis in a single round of screening using genomics, flow cytometry, and mass spectrometry. In particular, we identified BCAM as a promising candidate for targeted therapy in high-grade serous ovarian cancers. More generally, this approach provides a rapid and flexible framework to identify cancer targets and antibodies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Comprehensive evaluation of human-derived anti-poly-GA antibodies in cellular and animal models of C9orf72 disease.
- Author
-
Jambeau, Melanie, Meyer, Kevin D., Hruska-Plochan, Marian, Tabet, Ricardos, Chao-Zong Lee, Ray-Soni, Ananya, Aguilar, Corey, Savage, Kitty, Mishra, Nibha, Cavegn, Nicole, Borter, Petra, Chun-Chia Lin, Jansen-West, Karen R., Jie Jiang, Freyermuth, Fernande, Nan Li, De Rossi, Pierre, Pérez-Berlanga, Manuela, Xin Jiang, and Daughrity, Lilian M.
- Subjects
AMYOTROPHIC lateral sclerosis ,IMMUNOGLOBULINS ,IMMUNE complexes ,FRONTOTEMPORAL dementia - Abstract
Hexanucleotide G4C2 repeat expansions in the C9orf72 gene are the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia. Dipeptide repeat proteins (DPRs) generated by translation of repeat-containing RNAs show toxic effects in vivo as well as in vitro and are key targets for therapeutic intervention. We generated human antibodies that bind DPRs with high affinity and specificity. Anti-GA antibodies engaged extra- and intra-cellular poly-GA and reduced aggregate formation in a poly-GA overexpressing human cell line. However, antibody treatment in human neuronal cultures synthesizing exogenous poly-GA resulted in the formation of large extracellular immune complexes and did not affect accumulation of intracellular poly-GA aggregates. Treatment with antibodies was also shown to directly alter the morphological and biochemical properties of poly-GA and to shift poly-GA/antibody complexes to more rapidly sedimenting ones. These alterations were not observed with poly-GP and have important implications for accurate measurement of poly-GA levels including the need to evaluate all centrifugation fractions and disrupt the interaction between treatment antibodies and poly-GA by denaturation. Targeting poly-GA and poly-GP in two mouse models expressing G4C2 repeats by systemic antibody delivery for up to 16 mo was well-tolerated and led to measurable brain penetration of antibodies. Long-term treatment with anti-GA antibodies produced improvement in an open-field movement test in aged C9orf72450 mice. However, chronic administration of anti-GA antibodies in AAV-(G4C2)149 mice was associated with increased levels of poly-GA detected by immunoassay and did not significantly reduce poly-GA aggregates or alleviate disease progression in this model. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Anti-PF4 antibodies associated with disease severity in COVID-19.
- Author
-
Qingbo Liu, Huiyi Miao, Shuai Li, Peng Zhang, Gerber, Gloria F., Follmann, Dean, Hongkai Ji, Zeger, Scott L., Chertow, Daniel S., Quinn, Thomas C., Robinson, Matthew L., Kickler, Thomas S., Rothman, Richard E., Fenstermacher, Katherine Z. J., Braunstein, Evan M., Cox, Andrea L., Farci, Patrizia, Fauci, Anthony S., and Lusso, Paolo
- Subjects
HOSPITAL patients ,COVID-19 ,PATIENTS ,COVID-19 pandemic ,IMMUNOGLOBULINS ,AUTOPSY - Abstract
Severe COVID-19 is characterized by a prothrombotic state associated with thrombocytopenia, with microvascular thrombosis being almost invariably present in the lung and other organs at postmortem examination. We evaluated the presence of antibodies to platelet factor 4 (PF4)–polyanion complexes using a clinically validated immunoassay in 100 hospitalized patients with COVID-19 with moderate or severe disease (World Health Organization score, 4 to 10), 25 patients with acute COVID-19 visiting the emergency department, and 65 convalescent individuals. Anti-PF4 antibodies were detected in 95 of 100 hospitalized patients with COVID-19 (95.0%) irrespective of prior heparin treatment, with a mean optical density value of 0.871 ± 0.405 SD (range, 0.177 to 2.706). In contrast, patients hospitalized for severe acute respiratory disease unrelated to COVID-19 had markedly lower levels of the antibodies. In a high proportion of patients with COVID-19, levels of all three immunoglobulin (Ig) isotypes tested (IgG, IgM, and IgA) were simultaneously elevated. Antibody levels were higher in male than in female patients and higher in African Americans and Hispanics than in White patients. Anti-PF4 antibody levels were correlated with the maximum disease severity score and with significant reductions in circulating platelet counts during hospitalization. In individuals convalescent from COVID-19, the antibody levels returned to near-normal values. Sera from patients with COVID-19 induced higher levels of platelet activation than did sera from healthy blood donors, but the results were not correlated with the levels of anti-PF4 antibodies. These results demonstrate that the vast majority of patients with severe COVID-19 develop anti-PF4 antibodies, which may play a role in the clinical complications of COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
30. Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody.
- Author
-
Micalizzi, Douglas S., Dante Che, Nicholson, Benjamin T., Edd, Jon F., Desai, Niyati, Lang, Evan R., Toner, Mehmet, Maheswaran, Shyamala, Ting, David T., and Haber, Daniel A.
- Subjects
TRIPLE-negative breast cancer ,CELL junctions ,IMMUNOGLOBULINS ,EPITHELIAL cells - Abstract
The successful application of antibody-based therapeutics in either primary or metastatic cancer depends upon the selection of rare cell surface epitopes that distinguish cancer cells from surrounding normal epithelial cells. By contrast, as circulating tumor cells (CTCs) transit through the bloodstream, they are surrounded by hematopoietic cells with dramatically distinct cell surface proteins, greatly expanding the number of targetable epitopes. Here, we show that an antibody (23C6) against cadherin proteins effectively suppresses blood-borne metastasis in mouse isogenic and xenograft models of triple negative breast and pancreatic cancers. The 23C6 antibody is remarkable in that it recognizes both the epithelial E-cadherin (CDH1) and mesenchymal OB-cadherin (CDH11), thus overcoming considerable heterogeneity across tumor cells. Despite its efficacy against single cells in circulation, the antibody does not suppress primary tumor formation, nor does it elicit detectable toxicity in normal epithelial organs, where cadherins may be engaged within intercellular junctions and hence inaccessible for antibody binding. Antibody-mediated suppression of metastasis is comparable in matched immunocompetent and immunodeficient mouse models. Together, these studies raise the possibility of antibody targeting CTCs within the vasculature, thereby suppressing blood-borne metastasis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
31. Synthetic biology devices for in vitro and in vivo diagnostics.
- Author
-
Slomovic, Shimyn, Pardee, Keith, and Collins, James J.
- Subjects
SYNTHETIC biology ,MOLECULAR diagnosis ,IMMUNOGLOBULINS ,GENE regulatory networks ,DIAGNOSIS - Abstract
There is a growing need to enhance our capabilities in medical and environmental diagnostics. Synthetic biologists have begun to focus their biomolecular engineering approaches toward this goal, offering promising results that could lead to the development of new classes of inexpensive, rapidly deployable diagnostics. Many conventional diagnostics rely on antibody-based platforms that, although exquisitely sensitive, are slow and costly to generate and cannot readily confront rapidly emerging pathogens or be applied to orphan diseases. Synthetic biology, with its rational and short design-to-production cycles, has the potential to overcome many of these limitations. Synthetic biology devices, such as engineered gene circuits, bring new capabilities to molecular diagnostics, expanding the molecular detection palette, creating dynamic sensors, and untethering reactions from laboratory equipment. The field is also beginning to move toward in vivo diagnostics, which could provide near real-time surveillance of multiple pathological conditions. Here, we describe current efforts in synthetic biology, focusing on the translation of promising technologies into pragmatic diagnostic tools and platforms. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
32. Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion.
- Subjects
MEMBRANE fusion ,IMMUNOGLOBULINS ,EPITHELIAL cells ,LYMPHOPROLIFERATIVE disorders ,B cells - Abstract
Epstein-Barr virus (EBV) infects more than 90% of the world's adult population and accounts for a significant cancer burden of epithelial and B cell origins. Glycoprotein B (gB) is the primary fusogen essential for EBV entry into host cells. Here, we isolated two EBV gB-specific neutralizing antibodies, 3A3 and 3A5; both effectively neutralized the dual-tropic EBV infection of B and epithelial cells. In humanized mice, both antibodies showed effective protection from EBV-induced lymphoproliferative disorders. Cryoelectron microscopy analyses identified that 3A3 and 3A5 bind to nonoverlapping sites on domains D-II and D-IV, respectively. Structure-based mutagenesis revealed that 3A3 and 3A5 inhibit membrane fusion through different mechanisms involving the interference with gB-cell interaction and gB activation. Importantly, the 3A3 and 3A5 epitopes are major targets of protective gB-specific neutralizing antibodies elicited by natural EBV infection in humans, providing potential targets for antiviral therapies and vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. An anti-CTLA-4 heavy chain-only antibody with enhanced Treg depletion shows excellent preclinical efficacy and safety profile.
- Author
-
Xin Gan, Qianqian Shan, He Li, Janssens, Rick, Yuqiang Shen, Yun He, Fei Chen, van Haperen, Rien, Drabek, Dubravka, Jin Li, Yang Zhang, Jiuqiao Zhao, Beibei Qin, Ming-Jin Jheng, Chen, Victor, Jingsong Wang, Yiping Rong, and Grosveld, Frank
- Subjects
KRA ,IMMUNOGLOBULINS ,CELL physiology ,CYTOTOXIC T lymphocyte-associated molecule-4 ,CLINICAL medicine ,TRAFFIC safety ,EXPOSURE therapy - Abstract
The value of anti-CTLA-4 antibodies in cancer therapy is well established. However, the broad application of currently available anti-CTLA-4 therapeutic antibodies is hampered by their narrow therapeutic index. It is therefore challenging and attractive to develop the next generation of anti-CTLA-4 therapeutics with improved safety and efficacy. To this end, we generated fully human heavy chain-only antibodies (HCAbs) against CTLA-4. The hIgG1 Fc domain of the top candidate, HCAb 4003-1, was further engineered to enhance its regulatory T (Treg) cell depletion effect and to decrease its half-life, resulting in HCAb 4003-2. We tested these HCAbs in in vitro and in vivo experiments in comparison with ipilimumab and other anti-CTLA4 antibodies. The results show that human HCAb 4003-2 binds human CTLA-4 with high affinity and potently blocks the binding of B7-1 (CD80) and B7-2 (CD86) to CTLA-4. The results also show efficient tumor penetration. HCAb 4003-2 exhibits enhanced antibodydependent cellular cytotoxicity function, lower serum exposure, and more potent antitumor activity than ipilimumab in murine tumor models, which is partly driven by a substantial depletion of intratumoral Tregs. Importantly, the enhanced efficacy combined with the shorter serum half-life and less systemic drug exposure in vivo potentially provides an improved therapeutic window in cynomolgus monkeys and preliminary clinical applications. With its augmented efficacy via Treg depletion and improved safety profile, HCAb 4003-2 is a promising candidate for the development of next generation anti-CTLA-4 therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. Identification of the Bartonella autotransporter CFA as a protective antigen and hypervariable target of neutralizing antibodies in mice.
- Author
-
Siewert, Lena K., Korotaev, Aleksandr, Sedzicki, Jaroslaw, Fromm, Katja, Pinschewer, Daniel D., and Dehio, Christoph
- Subjects
BARTONELLA ,COMPLEMENT receptors ,FC receptors ,IMMUNOGLOBULINS ,ANTIGENS ,FIREPROOFING agents - Abstract
The bacterial genus Bartonella comprises numerous emerging pathogens that cause a broad spectrum of disease manifestations in humans. The targets and mechanisms of the anti-Bartonella immune defense are ill-defined and bacterial immune evasion strategies remain elusive. We found that experimentally infected mice resolved Bartonella infection by mounting antibody responses that neutralized the bacteria, preventing their attachment to erythrocytes and suppressing bacteremia independent of complement or Fc receptors. Bartonella-neutralizing antibody responses were rapidly induced and depended on CD40 signaling but not on affinity maturation. We cloned neutralizing monoclonal antibodies (mAbs) and by mass spectrometry identified the bacterial autotransporter CFA (CAMP-like factor autotransporter) as a neutralizing antibody target. Vaccination against CFA suppressed Bartonella bacteremia, validating CFA as a protective antigen. We mapped Bartonella-neutralizing mAb binding to a domain in CFA that we found is hypervariable in both human and mouse pathogenic strains, indicating mutational antibody evasion at the Bartonella subspecies level. These insights into Bartonella immunity and immune evasion provide a conceptual framework for vaccine development, identifying important challenges in this endeavor. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
35. Isotype-specific plasma cells express divergent transcriptional programs.
- Author
-
Higgins, Brett W., Shuparski, Andrew G., Miller, Karen B., Robinson, Amanda M., McHeyzer-Williams, Louise J., and McHeyzer-Williams, Michael G.
- Subjects
PLASMA cells ,GERMINAL centers ,CELL physiology ,IMMUNOGLOBULINS ,IMMUNITY - Abstract
Antibodies are produced across multiple isotypes with distinct properties that coordinate initial antigen clearance and confer long-term antigen-specific immune protection. Here, we interrogate the molecular programs of isotype-specific murine plasma cells (PC) following helper T cell-dependent immunization and within established steadystate immunity. We developed a single-cell-indexed and targeted molecular strategy to dissect conserved and divergent components of the rapid effector phase of antigenspecific IgM+ versus inflammation-modulating programs dictated by type 1 IgG2a/b
+ PC differentiation. During antibody affinity maturation, the germinal center (GC) cycle imparts separable programs for post-GC type 2 inhibitory IgG1+ and type 1 inflammatory IgG2a/b+ PC to direct long-term cellular function. In the steady state, two subsets of IgM+ and separate IgG2b+ PC programs clearly segregate from splenic type 3 IgA+ PC programs that emphasize mucosal barrier protection. These diverse isotype-specific molecular pathways of PC differentiation control complementary modules of antigen clearance and immune protection that could be selectively targeted for immunotherapeutic applications and vaccine design. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
36. Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface.
- Author
-
Xueyong Zhu, Julianna Han, Weina Sun, Puente-Massaguer, Eduard, Wenli Yu, Palese, Peter, Krammer, Florian, Ward, Andrew B., and Wilson, Ian A.
- Subjects
HEMAGGLUTININ ,INFLUENZA ,IMMUNOGLOBULINS ,X-ray crystallography ,VACCINE effectiveness - Abstract
Influenza virus hemagglutinin (HA) has been the primary target for influenza vaccine development. Broadly protective antibodies targeting conserved regions of the HA unlock the possibility of generating universal influenza immunity. Two group 2 influenza A chimeric HAs, cH4/3 and cH15/3, were previously designed to elicit antibodies to the conserved HA stem. Here, we show by X-ray crystallography and negative-stain electron microscopy that a broadly protective antistem antibody can stably bind to cH4/3 and cH15/3 HAs, thereby validating their potential as universal vaccine immunogens. Furthermore, flexibility was observed in the head domain of the chimeric HA structures, suggesting that antibodies could also potentially interact with the head interface epitope. Our structural and binding studies demonstrated that a broadly protective antihead trimeric interface antibody could indeed target the more open head domain of the cH15/3 HA trimer. Thus, in addition to inducing broadly protective antibodies against the conserved HA stem, chimeric HAs may also be able to elicit antibodies against the conserved trimer interface in the HA head domain, thereby increasing the vaccine efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
37. Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants.
- Author
-
Hong, Jessica, Hyung Joon Kwon, Raul Cachau, Chen, Catherine Z., Butay, Kevin John, Zhijian Duan, Dan Li, Hua Ren, Tianyuzhou Liang, Jianghai Zhu, Dandey, Venkata P., Martin, Negin P., Esposito, Dominic, Ortega-Rodriguez, Uriel, Miao Xu, Borgnia, Mario J., Hang Xie, and Mitchell Ho
- Subjects
SARS-CoV-2 ,IMMUNOGLOBULINS ,MIDDLE East respiratory syndrome ,CAMELS - Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike is a trimer of S1/S2 heterodimers with three receptor-binding domains (RBDs) at the S1 subunit for human angiotensin-converting enzyme 2 (hACE2). Due to their small size, nanobodies can recognize protein cavities that are not accessible to conventional antibodies. To isolate high-affinity nanobodies, large libraries with great diversity are highly desirable. Dromedary camels (Camelus dromedarius) are natural reservoirs of coronaviruses like Middle East respiratory syndrome CoV (MERS-CoV) that are transmitted to humans. Here, we built large dromedary camel V
H H phage libraries to isolate nanobodies that broadly neutralize SARS-CoV-2 variants. We isolated two VH H nanobodies, NCICoV-7A3 (7A3) and NCI-CoV-8A2 (8A2), which have a high affinity for the RBD via targeting nonoverlapping epitopes and show broad neutralization activity against SARS-CoV-2 and its emerging variants of concern. Cryoelectron microscopy (cryo-EM) complex structures revealed that 8A2 binds the RBD in its up mode with a long CDR3 loop directly involved in the ACE2 binding residues and that 7A3 targets a deeply buried region that uniquely extends from the S1 subunit to the apex of the S2 subunit regardless of the conformational state of the RBD. At a dose of ≥5 mg/kg, 7A3 efficiently protected transgenic mice expressing hACE2 from the lethal challenge of variants B.1.351 or B.1.617.2, suggesting its therapeutic use against COVID-19 variants. The dromedary camel VH H phage libraries could be helpful as a unique platform ready for quickly isolating potent nanobodies against future emerging viruses. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
38. Phenotypic determinism and stochasticity in antibody repertoires of clonally expanded plasma cells.
- Author
-
Neumeier, Daniel, Yermanos, Alexander, Agrafiotis, Andreas, Csepregi, Lucia, Chowdhury, Tasnia, Ehling, Roy A., Kuhn, Raphael, Cotet, Tudor-Stefan, Roberto, Raphaël Brisset-Di, Tacchio, Mariangela Di, Antonialli, Renan, Starkie, Dale, Lightwood, Daniel J., Oxenius, Annette, and Reddy, Sai T.
- Subjects
PLASMA cells ,PHENOTYPES ,IMMUNOGLOBULINS ,CELLULAR immunity ,VACCINE effectiveness ,GENETIC counseling - Abstract
The capacity of humoral B cell-mediated immunity to effectively respond to and protect against pathogenic infections is largely driven by the presence of a diverse repertoire of polyclonal antibodies in the serum, which are produced by plasma cells (PCs). Recent studies have started to reveal the balance between deterministic mechanisms and stochasticity of antibody repertoires on a genotypic level (i.e., clonal diversity, somatic hypermutation, and germline gene usage). However, it remains unclear if clonal selection and expansion of PCs follow any deterministic rules or are stochastic with regards to phenotypic antibody properties (i.e., antigen-binding, affinity, and epitope specificity). Here, we report on the in-depth genotypic and phenotypic characterization of clonally expanded PC antibody repertoires following protein immunization. We find that clonal expansion drives antigen specificity of the most expanded clones (top ∼10), whereas among the rest of the clonal repertoire antigen specificity is stochastic. Furthermore, we report both on a polyclonal repertoire and clonal lineage level that antibody-antigen binding affinity does not correlate with clonal expansion or somatic hypermutation. Last, we provide evidence for convergence toward targeting dominant epitopes despite clonal sequence diversity among the most expanded clones. Our results highlight the extent to which clonal expansion can be ascribed to antigen binding, affinity, and epitope specificity, and they have implications for the assessment of effective vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
39. Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidate.
- Author
-
Ruixue Wang, Suzuki, Saori, Guest, Johnathan D., Heller, Brigitte, Almeda, Maricar, Andrianov, Alexander K., Marin, Alexander, Mariuzza, Roy A., Zhen-Yong Keck, Foung, Steven K. H., Yunus, Abdul S., Pierce, Brian G., Toth, Eric A., Ploss, Alexander, and Fuerst, Thomas R.
- Subjects
HEPATITIS C virus ,HETERODIMERS ,CHRONIC hepatitis C ,IMMUNOGLOBULINS ,GLOBAL burden of disease - Abstract
Hepatitis C virus (HCV) is a global disease burden, and a preventive vaccine is needed to control or eradicate the virus. Despite the advent of effective antiviral therapy, this treatment is not accessible to many patients and does not prevent reinfection, making chronic hepatitis C an ongoing global health problem. Thus, development of a prophylactic vaccine will represent a significant step toward global eradication of HCV. HCV exhibits high genetic variability, which leads frequently to immune escape. However, a considerable challenge faced in HCV vaccine development is designing an antigen that elicits broadly neutralizing antibodies. Here, we characterized the immunogenicity of a vaccine based on a soluble, secreted form of the E1E2 envelope heterodimer (sE1E2.LZ). Sera from mice immunized with sE1E2.LZ exhibited an anti-E1E2-specific response comparable to mice immunized with membrane-bound E1E2 (mbE1E2) or a soluble E2 ectodomain (sE2). In competition-inhibition ELISA using antigenic domain-specific neutralizing and nonneutralizing antibodies, sera from sE1E2.LZ-immunized mice showed nearly identical or stronger competition toward neutralizing antibodies when compared with mbE1E2. In contrast, sera from mice immunized with sE2, and to a lesser extent mbE1E2, competed more effectively with nonneutralizing antibodies. An assessment of neutralization activity using both HCV pseudoparticles and cell culture-derived infectious HCV showed that immunization with sE1E2.LZ elicited the broadest neutralization activity of the three antigens, and sE1E2.LZ induced neutralization activity against all genotypes. These results indicate that our native-like soluble glycoprotein design, sE1E2.LZ, induces broadly neutralizing antibodies and serves as a promising vaccine candidate for further development. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
40. A novel mouse strain optimized for chronic human antibody administration.
- Author
-
Gupta, Aaron, Smith, Patrick, Bournazos, Stylianos, and Ravetch, Jeffrey V.
- Subjects
IDIOPATHIC thrombocytopenic purpura ,FC receptors ,TOXICITY testing ,IMMUNOGLOBULINS ,TRAFFIC safety ,IN vivo studies ,BEHAVIOR therapy - Abstract
Therapeutic human IgG antibodies are routinely tested in mouse models of oncologic, infectious, and autoimmune diseases. How- ever, assessing the efficacy and safety of long-term administration of these agents has been limited by endogenous anti-human IgG immune responses that act to clear human IgG from serum and relevant tissues, thereby reducing their efficacy and contributing to immune complex–mediated pathologies, confounding evaluation of potential toxicity. For this reason, human antibody treatment in mice is generally limited in duration and dosing, thus failing to recapitulate the potential clinical applications of these therapeu- tics. Here, we report the development of a mouse model that is tolerant of chronic human antibody administration. This model combines both a human IgG1 heavy chain knock-in and a full reca- pitulation of human Fc receptor (FcγR) expression, providing a unique platform for in vivo testing of human monoclonal antibod- ies with relevant receptors beyond the short term. Compared to controls, hIgG1 knock-in mice mount minimal anti-human IgG responses, allowing for the persistence of therapeutically active circulating human IgG even in the late stages of treatment in chronic models of immune thrombocytopenic purpura and meta- static melanoma. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. Switchable assembly and function of antibody complexes in vivo using a small molecule.
- Author
-
Martinko, Alexander J., Simonds, Erin F., Prasad, Suchitra, Ponce, Alberto, Bracken, Colton J., Junnian Wei, Yung-Hua Wang, Chow, Tiffany-Lynn, Zhong Huang, Evans, Michael J., Wells, James A., and Hill, Zachary B.
- Subjects
SMALL molecules ,BISPECIFIC antibodies ,MONOCLONAL antibodies ,IMMUNOGLOBULINS ,ANTIBODY-drug conjugates ,COMMERCIAL products - Abstract
The antigen specificity and long serum half-life of monoclonal antibodies have made them a critical part of modern therapeutics. These properties have been coopted in a number of synthetic formats, such as antibody–drug conjugates, bispecific antibodies, or Fc-fusion proteins to generate novel biologic drug modalities. Historically, these new therapies have been generated by covalently linking multiple molecular moieties through chemical or genetic methods. This irreversible fusion of different components means that the function of the molecule is static, as determined by the structure. Here, we report the development of a technology for switchable assembly of functional antibody complexes using chemically induced dimerization domains. This approach enables control of the antibody’s intended function in vivo by modulating the dose of a small molecule. We demonstrate this switchable assembly across three therapeutically relevant functionalities in vivo, including localization of a radionuclide-conjugated antibody to an antigen-positive tumor, extension of a cytokine’s halflife, and activation of bispecific, T cell–engaging antibodies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
42. Soothing touch of CD31 protects endothelium during cellular immune responses.
- Author
-
Thaunat, Olivier
- Subjects
CD31 antigen ,GENES ,IMMUNOGLOBULINS ,ENDOTHELIAL cells ,IMMUNOLOGIC diseases ,THERAPEUTICS - Abstract
The article discusses a research paper on the regulatory roles of CD31 immunoglobulin gene. It references the study "CD31 Signals Confer Immune Privilege to the Vascular Endothelium," in a 2015 issue of the "Proceedings of the National Academic of Sciences USA". It tackles the characteristics of CD31, the exposure of endothelial cells to various inflammatory stimuli in vitro, and the implications of the study for treatment for immune-mediated diseases.
- Published
- 2015
- Full Text
- View/download PDF
43. Autoreactive antibodies control blood glucose by regulating insulin homeostasis.
- Author
-
Amendt, Timm, Allies, Gabriele, Nicolò, Antonella, El Ayoubi, Omar, Young, Marc, Röszer, Tamás, Setz, Corinna S., Warnatz, Klaus, and Jumaa, Hassan
- Subjects
BLOOD sugar ,INSULIN ,HOMEOSTASIS ,IMMUNOGLOBULINS ,GLUCOSE metabolism ,HEMOPHILIACS - Abstract
Homeostasis of metabolism by hormone production is crucial for maintaining physiological integrity, as disbalance can cause severe metabolic disorders such as diabetes mellitus. Here, we show that antibody-deficient mice and immunodeficiency patients have sub-physiological blood glucose concentrations. Restoring blood glucose physiology required total IgG injections and insulin-specific IgG antibodies detected in total IgG preparations and in the serum of healthy individuals. In addition to the insulin-neutralizing anti-insulin IgG, we identified two fractions of anti-insulin IgM in the serum of healthy individuals. These autoreactive IgM fractions differ in their affinity to insulin. Interestingly, the low-affinity IgM fraction (anti-insulin IgM
low ) neutralizes insulin and leads to increased blood glucose, whereas the high-affinity IgM fraction (anti-insulin IgMhigh ) protects insulin from neutralization by anti-insulin IgG, thereby preventing blood glucose dysregulation. To demonstrate that anti-insulin IgMhigh acts as a protector of insulin and counteracts insulin neutralization by anti-insulin IgG, we expressed the variable regions of a high-affinity anti-insulin anti-body as IgG and IgM. Remarkably, the recombinant anti-insulin IgMhigh normalized insulin function and prevented IgG-mediated insulin neutralization. These results suggest that autoreactive anti-bodies recognizing insulin are key regulators of blood glucose and metabolism, as they control the concentration of insulin in the blood. Moreover, our data suggest that preventing autoimmune damage and maintaining physiological homeostasis requires adaptive tolerance mechanisms generating high-affinity autoreactive IgM antibodies during memory responses. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
44. Engineered human antibodies for the opsonization and killing of Staphylococcus aureus.
- Author
-
Xinhai Chen, Schneewind, Olaf, and Missiakas, Dominique
- Subjects
STAPHYLOCOCCUS aureus ,ASTHMATICS ,IMMUNOGLOBULINS ,FC receptors ,MONOCLONAL antibodies ,PHAGOCYTES ,HOSPITAL charges - Abstract
Gram-positive organisms with their thick envelope cannot be lysed by complement alone. Nonetheless, antibody-binding on the surface can recruit complement and mark these invaders for uptake and killing by phagocytes, a process known as opsonophagocytosis. The crystallizable fragment of immunoglobulins (Fc?) is key for complement recruitment. The cell surface of S. aureus is coated with Staphylococcal protein A (SpA). SpA captures the Fc? domain of IgG and interferes with opsonization by anti-S. aureus antibodies. In principle, the Fc? domain of therapeutic antibodies could be engineered to avoid the inhibitory activity of SpA. However, the SpA-binding site on Fc? overlaps with that of the neonatal Fc receptor (FcRn), an interaction that is critical for prolonging the half-life of serum IgG. This evolutionary adaptation poses a challenge for the exploration of Fc? mutants that can both weaken SpA-IgG interactions and retain stability. Here, we use both wildtype and transgenic human FcRn mice to identify antibodies with enhanced half-life and increased opsonophagocytic killing in models of S. aureus infection and demonstrate that antibody-based immunotherapy can be improved by modifying Fc?. Our experiments also show that by competing for FcRn-binding, staphylococci effectively reduce the half-life of antibodies during infection. These observations may have profound impact in treating cancer, autoimmune, and asthma patients colonized or infected with S. aureus and undergoing monoclonal antibody treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
45. Engineering pan-HIV-1 neutralization potency through multispecific antibody avidity.
- Author
-
Rujas, Edurne, Hong Cui, Burnie, Jonathan, Aschner, Clare Burn, Tiantian Zhao, Insausti, Sara, Muthuraman, Krithika, Semesi, Anthony, Ophel, Jasper, Nieva, Jose L., Seaman, Michael S., Guzzo, Christina, Treanor, Bebhinn, and Julien, Jean-Philippe
- Subjects
FC receptors ,IMMUNOGLOBULINS ,B cells ,HIV ,ENGINEERS - Abstract
Deep mining of B cell repertoires of HIV-1-infected individuals has resulted in the isolation of dozens of HIV-1 broadly neutralizing antibodies (bNAbs). Yet, it remains uncertain whether any such bNAbs alone are sufficiently broad and potent to deploy therapeutically. Here, we engineered HIV-1 bNAbs for their combination on a single multispecific and avid molecule via direct genetic fusion of their Fab fragments to the human apoferritin light chain. The resulting molecule demonstrated a remarkable median IC50 value of 0.0009 µg/mL and 100% neutralization coverage of a broad HIV-1 pseudovirus panel (118 isolates) at a 4 µg/mL cutoff--a 32-fold enhancement in viral neutralization potency compared to a mixture of the corresponding HIV-1 bNAbs. Importantly, Fc incorporation on the molecule and engineering to modulate Fc receptor binding resulted in IgG-like bioavailability in vivo. This robust plug-and-play antibody design is relevant against indications where multispecificity and avidity are leveraged simultaneously to mediate optimal biological activity. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
46. Anticancer efficacy of monotherapy with antibodies to SIRPa/SIRPß1 mediated by induction of antitumorigenic macrophages.
- Author
-
Mariko Sakamoto, Yoji Murata, Daisuke Tanaka, Yuka Kakuchi, Takeshi Okamoto, Daisuke Hazama, Yasuyuki Saito, Takenori Kotani, Hiroshi Ohnishi, Masayuki Miyasaka, Masato Fujisawa, and Takashi Matozaki
- Subjects
ANTINEOPLASTIC agents ,MACROPHAGES ,CANCER cells ,IMMUNOGLOBULINS ,PHAGOCYTOSIS ,CURCUMIN - Abstract
The interaction of signal regulatory protein a (SIRPa) on macrophages with CD47 on cancer cells is thought to prevent antibody (Ab)-dependent cellular phagocytosis (ADCP) of the latter cells by the former. Blockade of the CD47-SIRPa interaction by Abs to CD47 or to SIRPa, in combination with tumor-targeting Abs such as rituximab, thus inhibits tumor formation by promoting macrophage-mediated ADCP of cancer cells. Here we show that monotherapy with a monoclonal Ab (mAb) to SIRPa that also recognizes SIRPß1 inhibited tumor formation by bladder and mammary cancer cells in mice, with this inhibitory effect being largely dependent on macrophages. The mAb to SIRPa promoted polarization of tumor-infiltrating macrophages toward an antitumorigenic phenotype, resulting in the killing and phagocytosis of cancer cells by the macrophages. Ablation of SIRPa in mice did not prevent the inhibitory effect of the anti-SIRPa mAb on tumor formation or its promotion of the cancer cell-killing activity of macrophages, however. Moreover, knockdown of SIRPß1 in macrophages attenuated the stimulatory effect of the anti-SIRPa mAb on the killing of cancer cells, whereas an mAb specific for SIRPß1 mimicked the effect of the anti-SIRPa mAb. Our results thus suggest that monotherapy with Abs to SIRPa/SIRPß1 induces antitumorigenic macrophages and thereby inhibits tumor growth and that SIRPß1 is a potential target for cancer immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
47. Homogeneous antibody and CAR-T cells with improved effector functions targeting SSEA-4 glycan on pancreatic cancer.
- Author
-
Chih-Wei Lin, Yu-Jen Wang, Ting-Yen Lai, Tsui-Ling Hsu, Shin-Ying Han, Han-Chung Wu, Chia-Ning Shen, Dang, Van, Ming-Wei Chen, Lan-Bo Chen, and Chi-Huey Wong
- Subjects
PANCREATIC cancer ,IMMUNE response ,KILLER cells ,COMMERCIAL products ,IMMUNOGLOBULINS ,PANCREATIC diseases - Abstract
Pancreatic cancer is usually asymptomatic in the early stages; the 5-y survival rate is around 9%; and there is a lack of effective treatment. Here we show that SSEA-4 is more expressed in all pancreatic cancer cell lines examined but not detectable in normal pancreatic cells; and high expression of SSEA-4 or the key enzymes B3GALT5 + ST3GAL2 associated with SSEA-4 biosynthesis significantly lowers the overall survival rate. To evaluate potential new treatments for pancreatic cancer, homogeneous antibodies with a well-defined Fc glycan for optimal effector functions and CAR-T cells with scFv construct designed to target SSEA-4 were shown highly effective against pancreatic cancer in vitro and in vivo. This was further supported by the finding that a subpopulation of natural killer (NK) cells isolated by the homogeneous antibody exhibited enhancement in cancer-cell killing activity compared to the unseparated NK cells. These results indicate that targeting SSEA-4 by homologous antibodies or CAR-T strategies can effectively inhibit cancer growth, suggesting SSEA-4 as a potential immunotherapy target for treating pancreatic disease. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
48. Expression of the immunoglobulin C mu gene in mouse T and B lymphoid and myeloid cell lines.
- Author
-
Kemp DJ, Harris AW, Cory S, and Adams JM
- Subjects
- Animals, Cell Line, Genes, Granulocytes immunology, Immunoglobulin Light Chains genetics, Lymphoma immunology, Macrophages immunology, Mice, RNA, Messenger genetics, B-Lymphocytes immunology, Immunoglobulin Constant Regions genetics, Immunoglobulin Heavy Chains genetics, Immunoglobulin mu-Chains genetics, Immunoglobulins genetics, T-Lymphocytes immunology
- Abstract
We have used cloned nucleotide sequences as probes to search for immunoglobulin RNA in T and B lymphoid and nonlymphoid tumor cell lines. Polyadenylated RNA from the cells was fractionated electrophoretically by size and fixed to diazobenzyloxymethyl-paper, and then immunoglobulin RNA species were revealed by hybridization with 32P-labeled cloned sequences for mu heavy chain and kappa light chain. kappa mRNA was detected only in B lymphoid lines known to synthesize kappa chains. No mu RNA was detectable in erythroleukemia, mastocytoma, or sarcoma cells. RNA bearing mu constant region (C mu) sequences, however, was detected in four of nine T lymphoma and four of five myeloid tumor cell lines tested, as well as in B lymphoma and "pre-B" Abelson lymphoma cells. In contrast to the single mu RNA species of 2.6 kilobases (kb) in a plasmacytoma, individual T lymphoma and myeloid lines yielded up to three discrete mu RNA species of apparent size 1.9, 2.2, and 3.0 kb, each different from the two mu RNA species in a B lymphoma line (2.4 and 2.7 kb) or the single species in "pre-B" lymphoma cells (2.9 kb). Both chromosomal complements of the C mu gene in STRij-4 T cells were found to be rearranged from their embryonic (germ line) context. The results suggest that the C mu gene functions not only in T cells, wherein the ability to recognize antigen is long established, but also in myeloid cells.
- Published
- 1980
- Full Text
- View/download PDF
49. DNA sequences near the site of reciprocal recombination between a c-myc oncogene and an immunoglobulin switch region.
- Author
-
Dunnick W, Shell BE, and Dery C
- Subjects
- Animals, Base Sequence, Cell Line, DNA Restriction Enzymes, Immunoglobulin Constant Regions genetics, Immunoglobulin Heavy Chains genetics, Immunoglobulin Variable Region genetics, Mice, Nucleic Acid Hybridization, Plasmacytoma immunology, Cloning, Molecular, DNA, Recombinant, Genes, Immunoglobulins genetics, Oncogenes
- Abstract
The chromosomal translocations found in many B-cell tumors result in the joining of a c-myc oncogene with an immunoglobulin heavy chain switch region. This finding is striking because the natural function of switch regions is to mediate DNA rearrangements important to the maturation of immune responses. These normal switch rearrangements are probably mediated by specific enzymes. In this paper we report the isolation of the two reciprocal products of a recombination between a c-myc gene on murine chromosome 15 and an immunoglobulin switch region (S mu S gamma 2b) on chromosome 12. We have determined the sequences of these DNA molecules near the recombination sites and show that the recombination is nearly perfectly reciprocal, with a seven-nucleotide deletion. An examination of the sequences reported in this paper, and of sequences published by other authors, shows a correlation between the points of recombination for c-myc-S segment rearrangements and for normal heavy chain switches. We suggest that this correlation implies a role for switch recombination enzymes in creating substrates for the c-myc recombination. The c-myc gene also seems to share some limited homology to sequences thought to be important in heavy chain switching. Finally, we discuss a working model that accounts for some characteristics of c-myc-S segment recombinations. The model also suggests a mechanism for increased transcriptional activity of the rearranged c-myc oncogene in B-cell tumors.
- Published
- 1983
- Full Text
- View/download PDF
50. Hexavalent sperm-binding IgG antibody released from vaginal film for development of potent on-demand nonhormonal female contraception.
- Author
-
Shrestha, Bhawana, Vincent, Kathleen, Schaefer, Alison, Yong Zhu, Vargas, Gracie, Motamedi, Massoud, Swope, Kelsi, Morton, Josh, Simpson, Carrie, Pham, Henry, Brennan, Miles B., Pauly, Michael H., Zeitling, Larry, Bratcher, Barry, Whaley, Kevin J., Moench, Thomas R., and Lai, Samuel K.
- Subjects
IMMUNOGLOBULIN G ,CONTRACEPTION ,IMMUNOGLOBULINS ,MONOCLONAL antibodies ,HEALTH equity ,ANIMAL industry ,CATTLE fertility - Abstract
Nonhormonal products for on-demand contraception are a global health technology gap; this unmet need motivated us to pursue the use of sperm-binding monoclonal antibodies to enable effective on-demand contraception. Here, using the cGMP-compliant Nicotiana-expression system, we produced an ultrapotent spermbinding IgG antibody possessing 6 Fab arms per molecule that bind a well-established contraceptive antigen target, CD52g. We term this hexavalent antibody “Fab-IgG-Fab” (FIF). The Nicotianaproduced FIF had at least 10-fold greater sperm-agglutination potency and kinetics than the parent IgG, while preserving Fc-mediated trapping of individual spermatozoa in mucus. We formulated the Nicotiana-produced FIF into a polyvinyl alcohol–based water-soluble contraceptive film and evaluated its potency in reducing progressively motile sperm in the sheep vagina. Two minutes after vaginal instillation of human semen, no progressively motile sperm were recovered from the vaginas of sheep receiving FIF Film. Our work supports the potential of multivalent contraceptive antibodies to provide safe, effective, on-demand nonhormonal contraception. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.